Figure 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Year: 2025
Type: other
Abstract: ORR, CBR24, and median PFS for (A) camizestrant in combination with abemaciclib, palbociclib, or ribociclib; (B) subgroup analysis pooled across all camizestrant + CDK4/6i combinations. NC is represented by an arrowed line in the plots and is not representative of the data. N, no; NC, not calculated; Y, yes. Data in % represent 95% CI.
Authors: Richard D. Baird, Begoña Bermejo de las Heras, Manuel Ruiz-Borrego, Christos Vaklavas, Irene Moreno, Mafalda Oliveira, Anne Armstrong, Nicholas Turner, Jason Incorvati, Chris Twelves, Eva Ciruelos, Erika Hamilton, Manish R. Patel, Peter Kabos, Carmela Ciardullo, Teresa Klinowska, Justin P.O. Lindemann, Alastair M. Mathewson, Christopher J. Morrow, Andy Sykes, Jincheng Yang, Bairu Zhang, Ivan Victoria
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4415240849
Cites:
Cited by:
Related to: